Regencell Bioscience (RGC) - Long-Term Debt to Capital

This chart of Regencell Bioscience (RGC) asset value demonstrates the dynamics of a company developing autism and ADHD therapies based on Eastern medicine. The long-term debt-to-equity ratio is 0.00. The business relies on low price sensitivity of demand and the uniqueness of its formulas. However, the risk of funding shortages and failed tests could wipe out equity, while successful trials in Asia would become the primary growth driver.

This ratio reflects the balance sheet structure's dependence on long-term borrowings relative to equity, allowing for an assessment of the company's resilience to external shocks. By analyzing the ratio of long-term loans to equity, an investor can determine the degree of financial leverage, which is critical for an early-stage biotech like Regencell Bioscience (RGC), as the absence of revenue makes the company dependent on equity issuances rather than leverage.